

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,151,100 B1
APPLICATION NO. : 09/634207
DATED : December 19, 2006
INVENTOR(S) : Carson et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page, in item (63), under "Related U.S. Application Data", in column 1, line 2, after "1999" insert -- , now Pat. No. 6,545,034 --.

On the title page, in item (56), under "Foreign Patent Documents", in column 1, line 13, delete "WO-02/021225" and insert -- WO-02/02125 --, therefor.

On page 2, in item (56), under "U.S. Patent Documents", in column 1, line 32, below "5,824,699" insert -- 5,939,455 8/1999 Rephaeli 514/547 --.

On page 2, in item (56), under "U.S. Patent Documents", in column 1, line 43, below "2002/0042375" insert -- 2003/0004142 1/2003 Prior et al. 514/165 --.

On page 2, in item (56), under "Other Publications", in column 2, lines 38-41, delete ""Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation", Seminars in Surgical Oncology, 18(1), pp. 37-44, Jan./Feb. 2000)" and insert -- "Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)", European Journal of Cancer, 34 (8), pp. 1250-1259, (Jul. 1998). --, therefor.

On page 2, in item (56), under "Other Publications", in column 2, line 61, below "1997)." insert -- Leman, Eddy S., et al., "Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer", Journal of Cellular Biochemistry, 86, (2002), 203-212.--.

On page 3, in item (56), under "Other Publications", in column 2, line 7, delete "Etodalac" and insert -- Etodolac --, therefor.

On page 3, in item (56), under "Other Publications", in column 2, line 33, delete "Adenomas" and insert -- Adenomas --, therefor.

On page 3, in item (56), under "Other Publications", in column 2, line 37, delete "Flubiprofen" and insert -- Flurbiprofen --, therefor.

On page 3, in item (56), under "Other Publications", in column 2, line 38, delete "Enatiomer" and insert -- Enantiomer --, therefor.

On Sheet 4 of 15, in FIG. 4, line 7 (Excluding Graph), delete "50uM" and insert -- 50µM --, therefor.

In column 1, line 7, after "1999," insert -- now U.S. Patent No. 6,545,034, --.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,151,100 B1
APPLICATION NO. : 09/634207
DATED : December 19, 2006
INVENTOR(S) : Carson et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 2, lines 60–61, delete “1'-D-glucuronyloxy,” and insert -- $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)^+_3$, or 1'-D-glucuronyloxy; or Y-Z is $(\text{CH}_2)_{1-3}\text{R}^{10}$ wherein R^{10} is --, therefor.

In column 2, line 62, after “ $\text{PO}(\text{OH})\text{NH}_2$,” delete “ $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)^+_3$ ”.

In column 2, line 65, delete “calls” and insert -- cells --, therefor.

In column 3, line 9, delete “chromic” and insert -- chronic --, therefor.

In column 3, line 33, delete “chlorodenosine” and insert -- chloroadenosine --, therefor.

In column 3, line 34, delete “chemoterapeutic” and insert -- chemotherapeutic --, therefor.

In column 3, line 64, after “cancer” insert -- cell --.

In column 5, line 45, delete “or” and insert -- $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)^+_3$, --, therefor.

In column 5, line 46, after “alkylamino,” insert -- [(carboxy)(lower alkyl)] --.

In column 5, line 47, after “phenylamino,” insert -- or Y-Z is $(\text{CH}_2)_{1-3}\text{R}^{10}$ wherein R^{10} is --.

In column 5, line 48, after “ $\text{OCH}_2\text{CH}_2\text{N}(\text{CH}_3)^+_3$ ” insert -- , --.

In column 6, line 27, delete “metabolutes” and insert -- metabolites --, therefor.

In column 7, line 48, delete “to” and insert -- of --, therefor.

In column 8, line 47, delete “othewise” and insert -- otherwise --, therefor.

In column 9, line 38, after “the” insert -- preferred methods of preparation are vacuum drying and the freeze drying --.

In column 10, line 3, delete “Lymphocytes” and insert -- Lymphocytes --, therefor.

In column 10, line 59, delete “Chromagtog” and insert -- Chromatog --, therefor.

In column 14, line 4, delete “residuel” and insert -- residual --, therefor.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,151,100 B1
APPLICATION NO. : 09/634207
DATED : December 19, 2006
INVENTOR(S) : Carson et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 14, line 40, delete "radiolbeled" and insert -- radiolabeled --, therefor.


In column 14, line 47, delete "syste" and insert -- system --, therefor.

In column 14, line 60, delete "mg" and insert -- ng --, therefor.

In column 16, lines 27-34, in Claim 1, delete "wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or, together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R⁸), S or nonperoxide O; an amino acid ester of (ω -(HO)(C₂-C₄))alkoxy, N(R⁸)CH(R⁸)CO₂H, 1'-D-glucuronyloxy, OH, (C₂-C₄)acyloxy, SO₃H, PO₄H₂, N(NO)(OH), SO₂NH₂, PO(OH)(NH₂), OCH₂CH₂N(CH₃)₃⁺, amino, lower alkylamino, di(lower alkyl)amino, phenylamino," and insert -- an amino acid ester of (ω -(HO)(C₂-C₄))alkoxy, N(R⁸)CH(R⁸)CO₂H, 1'-D-glucuronyloxy, or OCH₂CH₂N(CH₃)₃⁺; wherein R⁸ and R⁹ are each H, (C₁-C₃)alkyl or together with N, are a 5- or 6-membered heterocyclic ring having 1-3 N(R⁸), S or nonperoxide O; or Y-Z is (CH₂)₁₋₃R¹⁰ wherein R¹⁰ is OH, (C₂-C₄)acyloxy, SO₃H, PO₄H₂, N(NO)(OH), SO₂NH₂, PO(OH)NH₂, --, therefor.

Signed and Sealed this

Twenty-fourth Day of July, 2007



JON W. DUDAS
Director of the United States Patent and Trademark Office